Oncology Research Office
What is a Clinical Trial?
Clinical trials are used to test, measure, and learn more about the effectiveness and risks of new treatments. After researchers explore experimental treatments in the laboratory, those with the most promising results move into clinical trials.
What are the benefits?
Participants gain access to new treatments before they are widely available, and help others by contributing to medical research that could lead to new breakthroughs.
Who can join a trial?
Participants must qualify based on specific guidelines. Some trials seek those with illnesses or conditions being studied, others need healthy participants.
How are people protected?
Trials are designed to protect participants and keep them safe. Risks and potential benefits are carefully explained, and participants may withdraw at any time. Ethical and legal codes governing medical practice apply to clinical trials, and most are federally regulated. An independent committee of physicians, statisticians, community advocates, and others provide approval and ongoing review to protect the rights of participants.
Clinical trials give our community access to the best research and next level of care. A recent commendation from the Commission on Cancer made particular note of the number of patients Sibley places in trials.
Please contact Amanda Moser
at (202) 660-6420 or by email firstname.lastname@example.org
to learn about the clinical trials offered at Sibley.
Open Protocol Information
Updated February 2, 2015
A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer
Johns Hopkins Breast Cancer Program Longitudinal Repository
Johns Hopkins Breast Cancer Program Hormone Therapy Longitudinal Database
J1232 (DIG-HIF1 PK)
Digoxin as a Novel Inhibitor of Global Hypoxia Inducible Factor-1α (HIF-1α) Expression & Downstream Targets in Breast Cancer: DIG-HIF1 Pharmacodynamic Trial
A Randomized Phase II Study of Partial Breast Irradiation and Sequential vs. Concurrent Chemotherapy in Women with ER Negative Early Stage Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Phase III Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER-2 Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial RX for Positive Node, Endocrine Responsive Breast Cancer
Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2-Directed Regimens in the Metastatic Setting
A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)
Combination immunotherapy with Herceptin and the HER2 vaccine E75 in low and intermediate HER2-expressing breast cancer patients to prevent recurrence
Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer
Detection and Prevention of Anthracycline-Related Cardiac Toxicity with Concurrent Simvastatin
A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Postmenopausal Patients with Hormone Receptor-Positive Advanced Breast Cancer
Correlation of Early Changes in SUV on PET with Pathological CR to Pertuzumab and Trastuzumab in Primary Operable HER2-Pos Breast Cancer
A Randomized Phase II Study of Adjuvant Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination with Trastuzumab for Stage I HER2-positive Breast Cancer
A Phase III trials of 6 versus 12 treatment of Adjuvant Treatment of Adjuvant Folfox plus Celecoxib or Placebo for patient with Resected Stage III Colon Cancer
PROSPECT: A Phase II/III trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision
Stereotactic Body Radiation Therapy and Short-Term Androgen Ablation for Intermediate-Risk, Localized, Adenocarcinoma of the Prostate
A Randomized Gene Fusion Stratified Phase 2 Trial Of Abiraterone With Or Without ABT 888 For Patients With Metastatic Castration-Resistant Prostate Cancer (NCI# 9012)
Understanding Mechanisms of Response and Resistance to Androgen-Directed Therapies in Men with Advanced Prostate Cancer Through Interrogation of Tumor Biopsies: A Pilot/Feasibility Study
Development and Evaluation of Tumor Markers for Clinically Significant Prostate Cancer
Immune Evaluation Study of Sipuleucel-T in African American and European American Men with Castrate Resistant Prostate Cancer
A Phase II Protocol for Patients with Stage T1 Bladder Cancer to Evaluate Selective Bladder Preserving Treatment by Radiation Therapy Concurrent with Radiosensitizing Chemotherapy Following a Thorough Transurethral Surgical Re-Staging
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy TAK-700 With Androgen Deprivation Therapy Bicalutamide in Patients With Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men with Non-Metastatic (M0) Castration-Resistant Prostate Cancer
Observational Longitudinal Study of Pain in Men with Metastatic Castrate-Resistant Prostate Cancer
Abiraterone alone, abiraterone plus degarelix, a GnRH antagonist, and degarelix alone for prostate ca w/ rising PSA or a rising PSA and nodal disease following definitive radical prostatectomy
Race as a Risk Factor for Metastatic Prostate Cancer: A Sentinel Event Case Series
A Phase II Study to Determine Sequential Response to Bipolar Androgen Therapy (BAT) followed by Enzalutamide or Abiraterone Post-BAT in Men with Prostate Cancer Progressing on Combined Androgen Ablative Therapies
Phase III Trial of Enzalutamide (NSC # 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
Active Surveillance of Prostate Cancer
A biospecimen bank and study to understand genitourinary cancer and other benign urologic conditions.
A Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation In Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy.
A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin In Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
A Phase III Randomized Trial of Gemcitabine plus Docetaxel Followed by Doxorubicin versus Observation for Uterus-Limited High-Grade Uterine Leiomyosarcoma
Concurrent Chemotherapy and Pelvic RT w/wo Adj Chemo in High-Risk Pts with Early-Stage Cervical Ca following Radical Hysterectomy
A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features
Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC
Amgen: Evaluate the Long-Term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects w/ Advanced Stage NSCLC Receiving Multi-Cycle Chemo
There are no open studies at this time.
There are no open studies at this time.